News Image

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Provided By GlobeNewswire

Last update: Sep 24, 2025

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- DarĂ© Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced it has entered into an agreement with the Gates Foundation under which it will receive up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for third-party research projects addressing preeclampsia, one of the most serious and underserved complications of pregnancy.

Read more at globenewswire.com

DARE BIOSCIENCE INC

NASDAQ:DARE (10/3/2025, 8:00:01 PM)

After market: 2.1503 -0.03 (-1.36%)

2.18

+0.03 (+1.4%)



Find more stocks in the Stock Screener

Follow ChartMill for more